Product Name: RSK1 (217-224) pY220+pS221
Product Number: PE-04AHT95
| Size: | 200 µg | Price: | 69.00 | |
| 1 mg | $US | 139.00 | ||
| 5 mg | 304.00 |
Peptide Name: RSK1 (217-224) pY220+pS221
Product Use: Services as a blocking peptide for use with the RSK1-pY220+pS221 rabbit polyclonal antibody (Cat. No.: AB-PK807) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. These are two of the major in vivo phosphorylation sites in RSK1. Y220 and S221 phosphorylation is predicted to stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: KKA-pY-pS-FCG
Peptide Modifications N Terminus: Free amino
Product Use: Services as a blocking peptide for use with the RSK1-pY220+pS221 rabbit polyclonal antibody (Cat. No.: AB-PK807) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. These are two of the major in vivo phosphorylation sites in RSK1. Y220 and S221 phosphorylation is predicted to stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: KKA-pY-pS-FCG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1236.24 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: RSK1 - pY220+pS221 phosphosite-specific antibody (Cat. No.: AB-PK807)
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1236.24 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: RSK1 - pY220+pS221 phosphosite-specific antibody (Cat. No.: AB-PK807)
Scientific Background: RSK1 (RPS6KA1) is a protein-serine/threonine kinase of the AGC group and RSK family, which features two kinase catalytic domains on the same polypeptide chain. This kinase is highly expressed and widely distributed in most tested human tissues. RSK1 transcript is present in lymphocytes, skeletal muscle, liver, and adipose tissue. RSK1 is activated by phosphorylation at S363, S380 and T573. Phosphorylation at S221 by PDK1 is required for increased phosphotransferase activity, but is insufficient by itself. Phosphorylation at S154 induces interaction with 14-3-3 and inhibits catalytic activity. RSKs are implicated in the activation of the mitogen-activated kinase (MAPK) cascade and the stimulation of cell proliferation and differentiation. RSK1 forms a complex with either ERK1 or ERK2 in quiescent cells, and phosphorylation of S732 in response to mitogenic stimulation of cells permits dissociation of RSK-ERK complexes. RSK1 is known phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway -- a pro-growth/anti-apoptotic pathway, as it will activate CREB, which in turn will upregulate expression of cyclin-D and c-Myc. Activation of this pathway is common in various types of tumours. RSK1 may be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. Abnormal activation of RSK1 expression has been linked to many human diseases, including breast and prostate cancers. Inhibition of RSK signalling enhances the effects of enzalutamide prostate cancer therapy.
© Kinexus Bioinformatics Corporation 2017